Brief: Marker Therapeutics Announces Sustained Complete Response In First Lymphoma Patient Treated With MT-601 Following Car T Relapse
11/12/2023 12:12
Dec 11 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS ANNOUNCES SUSTAINED COMPLETE RESPONSE
IN
FIRST LYMPHOMA PATIENT TREATED WITH MT-601 FOLLOWING CAR T
RELAPSE
Source text for Eikon: ID:nGNX8RyZMS
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79